GlassScriptPhysician profile
Candyce Poteet
NPI 1609155761
$896.81
in general payments reported to CMS, 2019-2025
16 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.04 · 2022: $49.75 · 2023: $128 · 2024: $506 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.00 | 2024 | Relistor |
| Abbvie INC. | $116.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $110.43 | 2022-2025 | Tagrisso |
| Janssen Biotech, INC. | $101.29 | 2023-2024 | Tecvayli, Talvey, Darzalex |
| Ipsen Biopharmaceuticals, INC | $68.41 | 2024-2025 | Onivyde |
| Merck Sharp & Dohme LLC | $62.30 | 2024 | Keytruda |
| Regeneron Healthcare Solutions, INC. | $52.47 | 2023 | Libtayo |
| Genentech USA, INC. | $49.88 | 2024-2025 | Polivy, Venclexta |
| Pharmacosmos Therapeutics INC. | $49.15 | 2025 | Monoferric |
| Novartis Pharmaceuticals Corporation | $34.03 | 2025 | |
| Eisai INC. | $24.88 | 2024 | |
| Gilead Sciences, INC. | $24.80 | 2024 | |
| Jazz Pharmaceuticals INC. | $22.66 | 2024 | |
| Genmab U.S., INC. | $21.21 | 2024 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $19.41 | 2023 | Imbruvica |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $17.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candyce Poteet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.